Research overview
Overview
Oncological Oblivion in Cancer Survivorship: Psychosocial, Medical and Legal Implications in a Comparative European Perspective
Journal: BRAIN. Broad Research in Artificial Intelligence and Neuroscience · Volume 17, Issue 3 · PDF pages 544–565
Publication: September 2026 · Submitted: 24 July 2026 · Accepted: 23 August 2026
The article's suggested citation gives pages 544–564, while its PDF header and final page give 544–565. Source article © 2026 EduSoft Publishing · CC BY-NC-ND.
A diagnosis
is not a destiny.
Oncological oblivion protects people who have overcome cancer from the unnecessary use of past health information. The article connects that right with dignity, social reintegration, patient autonomy and safe continuity of care.
Protect participationA past diagnosis should not automatically limit work, finance or family life.
Keep care continuousClinically relevant history still matters for safe healthcare.
Respect autonomyPatients retain control over appropriate disclosure and access to health data.
From erasing history to preventing its misuse
Erase every trace of the diagnosis
Thinking of oblivion as total deletion overlooks the continuing clinical value of medical history and follow-up information.
Limit irrelevant use; retain necessary care
The right protects survivors from discrimination while preserving information needed for safe and continuous healthcare.
This four-stage route is an explanatory synthesis. The article treats oncological oblivion as part of a wider survivorship paradigm, not as deletion of all historical medical data.
Four national approaches, different scopes
The waiting period is only one part of protection. The areas covered and the handling of health information matter just as much.
A broader right reaches beyond financial products.
Law No. 193/2023 covers insurance and financial services, adoption, employment, vocational training and competitive or selective procedures.
Generally 10 years after active treatment ends, or 5 years if diagnosed before age 21; shorter periods apply to certain cancers.
*Both Italy and the Netherlands have shorter periods for certain cancers. The article cautions that these systems differ in scope and operation. These are legal thresholds, not a universal medical threshold.
Six themes drawn from the article
A survivor is more than a historical diagnosis.
Recovery includes a return to ordinary social roles without being continually defined by previous cancer.
This six-theme grouping is an overview synthesis, not an enumerated model in the article.
Protected in society. Informed in care.
The article separates the social use of old cancer information from access needed for treatment and follow-up.
Past cancer information can remain in a medical record.
The right to oncological oblivion does not require healthcare systems to erase all clinically relevant history.
The four steps illustrate the article's distinction between disclosure in social settings and clinically justified access; they are not a prescribed process.
Digital records make the boundary practical
Who may see past cancer information, and for what purpose?
Electronic records can improve communication across care settings. Their value depends on appropriate access, confidentiality and patient control.
Availability of data is distinct from permission to consult or reuse it.
Keep the record accurate
Clear and complete clinical documentation supports safe follow-up and continuity of care.
Limit consultation to a legitimate purpose
In the Italian FSE framework, storing a document and consulting its contents are different actions, with applicable consent and access rules.
Give patients visibility and control
Access logging, visibility controls and the possibility of revoking consultation consent support informational autonomy.
Share with caregivers appropriately
Family support does not create an unrestricted right to the patient’s health information; sharing should reflect wishes and care needs.
A conceptual synthesis, not an outcome study.
The paper draws on law and interdisciplinary literature. It has no original empirical sample and compares four European countries.
Research priority
Study how survivors experience stigma, disclosure, social participation and the use of the right in everyday settings.
Policy question
Review waiting periods against evolving evidence while retaining clinically necessary information for safe care.